Matthew J. Matasar, MD

home / authors / matt-matasar-md

Matthew J. Matasar, MD, is a hematologist/oncologist and chief, Division of Blood Disorders, at the Rutgers Cancer Institute, as well as a professor of medicine at Rutgers Robert Wood Johnson Medical School.

Articles

Loncastuximab Shows Durable Response in Higher-Risk R/R DLBCL Population

Loncastuximab Shows Durable Response in Higher-Risk R/R DLBCL Population

Matthew J. Matasar, MD
August 5th 2022

Matthew J. Matasar, MD, discusses the LOTIS-2 trial of loncastuximab tesirine in patients with relapsed/refractory diffuse large B-cell lymphoma.

Changes in the Treatment Landscape for Patients With DLBCL

Changes in the Treatment Landscape for Patients With DLBCL

Matthew J. Matasar, MD
June 1st 2022

Matthew J. Matasar, MD, discusses the current landscape of diffuse large B-cell lymphoma.

New Treatment Regimen Examined in POLARIX Trial for Patients With DLBCL

New Treatment Regimen Examined in POLARIX Trial for Patients With DLBCL

Matthew J. Matasar, MD
April 16th 2022

Matthew J. Matasar, MD, discusses how updates in the diffuse large B-cell lymphoma field have led to improved quality of life in patients.

Matasar Considers Treatment Options in B-Cell Lymphoma

Matasar Considers Treatment Options in B-Cell Lymphoma

Matthew J. Matasar, MD
September 29th 2021

Matt Matasar, MD, discusses treatment options in B-cell lymphomas.

<12

Latest Updated Articles

FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
POLL: What Frontline Treatment Would You Choose for Favorable- and Intermediate-Risk RCC?
Published: August 29th 2022 | Updated: December 4th 2024
POLL: What Frontline Treatment Would You Choose for Favorable- and Intermediate-Risk RCC?
Reviewing the Choice of First-Line Combinations for Clear Cell RCC and Other Histologies
Published: July 15th 2022 | Updated: December 4th 2024
Reviewing the Choice of First-Line Combinations for Clear Cell RCC and Other Histologies
Bridging Options for CAR T-Cell Therapy in R/R DLBCL
Published: January 6th 2023 | Updated: December 4th 2024
Bridging Options for CAR T-Cell Therapy in R/R DLBCL
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
Published: November 13th 2024 | Updated: December 4th 2024
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
The Targeted Pulse: Unlock Recent FDA Highlights in Leukemia and Prostate Cancer and An Interesting Vaccine Gaining Traction in Triple-Negative Breast Cancer
Published: December 1st 2024 | Updated: December 4th 2024
The Targeted Pulse: Unlock Recent FDA Highlights in Leukemia and Prostate Cancer and An Interesting Vaccine Gaining Traction in Triple-Negative Breast Cancer